Werner, Marcela S.
Aras, Shweta
Morgan, Ashleigh R.
Roamer, Jillian
Param, Nesteene J.
Olagbegi, Kanyin
Lamontagne, R. Jason http://orcid.org/0000-0002-9068-3348
Greig, Jenny A.
Wilson, James M. http://orcid.org/0000-0002-9630-3131
Funding for this research was provided by:
This study was supported by G2 Oncology.
Article History
Received: 19 September 2023
Revised: 5 February 2024
Accepted: 16 February 2024
First Online: 13 March 2024
Competing interests
: JMW is a paid advisor to and holds equity in iECURE, Scout Bio, Passage Bio, and the Center for Breakthrough Medicines (CBM). He also holds equity in the former G2 Bio asset companies. He has sponsored research agreements with Amicus Therapeutics, CBM, Elaaj Bio, FA212, Foundation for Angelman Syndrome Therapeutics, former G2 Bio asset companies, iECURE, Passage Bio, and Scout Bio, which are licensees of Penn technology. JAG and JMW are inventors on patents that have been licensed to various biopharmaceutical companies and for which they may receive payments. The other authors have no disclosures to declare.
: All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania.